Geron Co. (NASDAQ:GERN)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $6.99 and last traded at $5.59, with a volume of 1312010 shares changing hands. The stock had previously closed at $6.89.

GERN has been the subject of several research analyst reports. BidaskClub downgraded shares of Geron from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. ValuEngine raised shares of Geron from a “hold” rating to a “buy” rating in a research note on Wednesday, May 23rd. B. Riley initiated coverage on shares of Geron in a research note on Thursday, July 5th. They issued a “buy” rating and a $5.75 price target for the company. Finally, FBR & Co initiated coverage on shares of Geron in a research note on Thursday, July 5th. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Geron presently has a consensus rating of “Buy” and a consensus target price of $5.31.

The company has a market cap of $1.06 billion, a price-to-earnings ratio of -31.06 and a beta of 3.13.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative net margin of 3,232.73% and a negative return on equity of 23.15%. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.21 million. research analysts predict that Geron Co. will post 0.39 EPS for the current fiscal year.

In other Geron news, EVP Stephen Rosenfield sold 1,362,250 shares of Geron stock in a transaction on Friday, August 24th. The shares were sold at an average price of $4.51, for a total value of $6,143,747.50. Following the completion of the sale, the executive vice president now directly owns 36,000 shares of the company’s stock, valued at $162,360. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of GERN. BlackRock Inc. increased its position in shares of Geron by 13.2% during the second quarter. BlackRock Inc. now owns 13,388,978 shares of the biopharmaceutical company’s stock worth $45,924,000 after acquiring an additional 1,556,478 shares in the last quarter. Bank of America Corp DE increased its position in shares of Geron by 307.6% during the second quarter. Bank of America Corp DE now owns 1,257,098 shares of the biopharmaceutical company’s stock worth $4,313,000 after acquiring an additional 948,680 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Geron by 16.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 343,000 shares of the biopharmaceutical company’s stock worth $1,177,000 after acquiring an additional 49,600 shares in the last quarter. Creative Planning increased its position in shares of Geron by 53.4% during the second quarter. Creative Planning now owns 319,311 shares of the biopharmaceutical company’s stock worth $1,095,000 after acquiring an additional 111,208 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Geron by 13.1% during the first quarter. Swiss National Bank now owns 284,400 shares of the biopharmaceutical company’s stock worth $1,209,000 after acquiring an additional 32,900 shares in the last quarter. 37.17% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile (NASDAQ:GERN)

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Featured Article: Trading Penny Stocks

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.